blinatumomab
UK's NICE Approves Blincyto as Frontline Consolidation Treatment for Certain Leukemia Patients
Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.
Amgen Reports More Than $2B in Oncology Revenues in Q4
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
EC Approves Amgen's Blincyto as Consolidation Treatment for Certain Newly Diagnosed Leukemia Cases
The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.
Amgen Sees Strong Growth for Precision Oncology Drugs in Q3
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
Feb 7, 2024
Oct 31, 2023